Long-term pharmacotherapy for post-traumatic stress disorder

CNS Drugs

Volumn 20, Issue 6, 2006, Pages 465-476

  Davis, Lori L ^a,b   Frazier, Elizabeth C ^b   Williford, Raela B ^a   Newell, Jason M ^a,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUOXETINE; NEFAZODONE; PAROXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VALPROIC ACID;

CLINICAL TRIAL; DRUG EFFICACY; HUMAN; MEDICAL LITERATURE; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REVIEW; RISK;

ANTIPSYCHOTIC AGENTS; HUMANS; PUBMED; SEROTONIN UPTAKE INHIBITORS; STRESS DISORDERS, POST-TRAUMATIC; TIME;

EID: 33744791753     PISSN: 11727047     EISSN: 11727047     Source Type: Journal    
DOI: 10.2165/00023210-200620060-00003     Document Type: Review

References (32)

1. Kessler RC, Sonnega A, Bromet E, et al. Posttraumatic stress disorder in the national comorbidity survey. Arch Gen Psychiatry 1995; 52: 1048-60
2. Kulka RL, Schlenger WE, Fairbank JA, et al. The National Vietnam Veterans Readjustment Study: tables of findings and technical appendices. New York: Brunner/Mazel Publishers, 1990
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. (DSM-III). Washington, DC: American Psychiatric Association, 1980
4. Davis LL, English BA, Ambrose SA, et al. Pharmacotherapy for posttraumatic stress disorder: a comprehensive review. Expert Opin Pharmacother 2001; 2 (10): 1583-95
5. Asnis GM, Kohn SR, Henderson M, et al. SSRIs versus non-SSRIs in posttraumatic stress disorder: an update with recommendations. Drugs 2004; 64 (4): 383-404
6. Comer AM, Figgitt DP. Sertraline: a review of its therapeutic use in post-traumatic stress disorder. CNS Drugs 2000 Nov; 14 (5): 391-407
7. Expert Consensus Panels for PTSD. Treatment of posttraumatic stress disorder. J Clin Psychiatry 1999; 60 (16 Suppl.): 1-76
8. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement update on posttraumatic stress disorder from the International Consensus Group on depression and anxiety. J Clin Psychiatry 2004; 65 (1 Suppl.): 55-62
9. American Psychiatric Association Work Group on Acute Stress Disorder and PTSD. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. Am J Psychiatry 2004 Nov; 161 Suppl. 11: 1-31
10. Brady K, Pearlstein T, Asnis GM, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000 Apr 12; 282: 1837-44
11. Davidson JR, Rothbaum BO, van der Kolk BA, et al. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001; 58: 485-92
12. Marshall RD, Beebe KL, Oldham M, et al. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001; 158: 1982-8
13. Tucker P, Zaninelli R, Yehuda R, et al. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled flexible-dosage trial. J Clin Psychiatry 2001; 62: 860-8
14. Londborg PD, Hegel M, Goldstein S, et al. Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open label continuation treatment. J Clin Psychiatry 2001 May; 62 (5): 325-31
15. Davidson J, Pearlstein T, Londborg P, et al. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 2001; 158: 1974-81
16. Rapaport MH, Endicott J, Clary CM. Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. J Clin Psychiatry 2002 Jan; 63 (1): 59-65
17. Vermetten E, Vythilingham M, Southwick SM, et al. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry 2003; 54: 693-702
18. Martenyi F, Brown EB, Zhang H, et al. Fluoxetine versus placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry 2002; 181: 315-20
19. Bartzokis G, Lu PH, Turner J, et al. Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry 2005; 57: 474-9
20. Wheatley M, Plant J, Reader H, et al. Clozapine treatment of adolescents with posttraumatic stress disorder and psychotic symptoms. J Clin Psychopharmacol 2004; 24 (2): 167-73
21. Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry 1991 Sep; 52 (9): 361-4
22. Hertzberg MH, Feldman ME, Beckham JC, et al. Three- to four-year follow-up to an open trial of nefazodone for combat-related posttraumatic stress disorder. Ann Clin Psychiatry 2002; 14 (4): 215-21
23. Martenyi F, Brown EB, Zhang H, et al. Fluoxetine versus placebo for posttraumatic stress disorder. J Clin Psychiatry 2002 Mar; 63 (3): 199-206
24. Hamner MB, Robert S. Emerging roles for atypical antipsychotics in chronic post-traumatic stress disorder. Expert Rev Neurother 2005; 5 (2): 267-75
25. Hamner MB, Robert S, Frueh BC. Treatment-resistant posttraumatic stress disorder: strategies for intervention. CNS Spectrums 2004 Oct; 9 (10): 740-52
26. Lipper S, Davidson JRT, Grady TA, et al. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics 1986; 27: 849-54
27. Petty F, Davis L, Nugent AL, et al. Valproate therapy for chronic combat induced posttraumatic stress disorder. J Clin Psychopharmacol 2002; 22 (1): 100-1
28. Berlant J. Prospective open label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder. BMC Psychiatry 2004; 4: 24
29. Bremner JD, Mletzko T, Welter S, et al. Effects of phenytoin on memory, cognition and brain structure in post-traumatic stress disorder: a pilot study. J Psychopharmacol 2005; 19 (2): 159-65
30. Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999; 45 (9): 1226-9
31. Foa EB. Psychosocial treatment of posttraumatic stress disorder. J Clin Psychiatry 2000; 61 (5 Suppl.): 43-8
32. Stein DJ, Bandelow B, Hollander E, et al. WCA recommendations for the long-term treatment of posttraumatic stress disorder. CNS Spectr 2003; 8 (8): 31-9